We are live on !
Find out more
Marshall Wace Portfolio holdings
AUM
$127B
Turnover
40.17%
1-Year Est. Return
46.06%
This Fund
S&P 500
This Quarter Est. Return
+26.15%
1 Year Est. Return
+46.06%
3 Year Est. Return
+142.12%
5 Year Est. Return
+190.33%
10 Year Est. Return
+787.47%
AUM
$127B
AUM Growth
+$26.3B
(+26%)
Cap. Flow
+$9.28B
Cap. Flow % of AUM
Cap. Flow %
7.32%
Top 10 Holdings %
Top 10 Hldgs %
37.66%
Holding
3,898
New
771
Increased
1,083
Reduced
1,182
Closed
795
Avg Time Held
Equity + Options
1
year
Top 10 Avg Time Held
Equity + Options
2.3
years
Top 20 Avg Time Held
Equity + Options
1.6
years
Avg Time Held Equity only
1
year
Top 10 Avg Time Held Equity only
2.4
years
Top 20 Avg Time Held Equity only
1.6
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Core S&P 500 ETF
IVV
|
+$9.9B |
| 2 |
Costco
COST
|
+$907M |
| 3 |
AbbVie
ABBV
|
+$643M |
| 4 |
JPMorgan Chase
JPM
|
+$609M |
| 5 |
Bank of America
BAC
|
+$567M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$1.03B |
| 2 |
Mercado Libre
MELI
|
+$528M |
| 3 |
Broadcom
AVGO
|
+$514M |
| 4 |
Sandisk
SNDK
|
+$507M |
| 5 |
Marvell Technology
MRVL
|
+$499M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 34.91% |
| 2 | Technology | 20.64% |
| 3 | Consumer Discretionary | 9.1% |
| 4 | Healthcare | 8.21% |
| 5 | Financials | 7.4% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
2026
MGP Ingredients
MGPI
$337M
| $1.37M | ﹤0.01% |
77,980
-82,401
| -51% | -$1.5M |
2023 Q3
11 quarters
|
|
2027
WEX
WEX
$6.73B
| $1.37M | ﹤0.01% |
9,680
+2,000
| +26% | +$296K |
2023 Q3
11 quarters
|
|
2028
CALL
State Street Energy Select Sector SPDR ETF
XLE
$46B
| $1.36M | ﹤0.01% |
25,600
-853,600
| -97% | -$48.8M |
2026 Q1
1 quarter
|
|
2029
Pennant Park Investment Corp
PNNT
$187M
| $1.36M | ﹤0.01% |
+391,726
| New | +$1.63M |
2026 Q2
0 quarters
|
|
2030
Seres Therapeutics
MCRB
$21M
| $1.36M | ﹤0.01% |
172,245
+32,706
| +23% | +$249K |
2025 Q2
4 quarters
|
|
2031
National Beverage
FIZZ
$3.38B
| $1.35M | ﹤0.01% |
+43,332
| New | +$1.51M |
2026 Q2
0 quarters
|
|
2032
Expensify
EXFY
$236M
| $1.35M | ﹤0.01% |
751,773
-162,536
| -18% | -$182K |
2024 Q2
8 quarters
|
|
2033
Agenus
AGEN
$286M
| $1.35M | ﹤0.01% |
439,621
-248,582
| -36% | -$891K |
2025 Q2
4 quarters
|
|
2034
Northern Oil and Gas
NOG
$3.01B
| $1.34M | ﹤0.01% |
73,783
-204,234
| -73% | -$4.84M |
2026 Q1
1 quarter
|
|
2035
ARKO Petroleum
APC
$755M
| $1.34M | ﹤0.01% |
71,014
-29,818
| -30% | -$572K |
2026 Q1
1 quarter
|
|
2036
GE HealthCare
GEHC
$32.3B
| $1.34M | ﹤0.01% |
20,900
-151,105
| -88% | -$9.9M |
2025 Q4
2 quarters
|
|
2037
Bright Horizons
BFAM
$3.47B
| $1.34M | ﹤0.01% |
18,842
-270,190
| -93% | -$19.5M |
2022 Q2
16 quarters
|
|
2038
Innovex International
INVX
$2.09B
| $1.33M | ﹤0.01% |
53,766
-12,426
| -19% | -$338K |
2026 Q1
1 quarter
|
|
2039
Fate Therapeutics
FATE
$253M
| $1.33M | ﹤0.01% |
+492,426
| New | +$911K |
2026 Q2
0 quarters
|
|
2040
Southern First Bancshares
SFST
$580M
| $1.33M | ﹤0.01% |
21,693
-2,908
| -12% | -$168K |
2025 Q3
3 quarters
|
|
2041
BGC Group
BGC
$5.5B
| $1.33M | ﹤0.01% |
+123,956
| New | +$1.39M |
2026 Q2
0 quarters
|
|
2042
Century Therapeutics
IPSC
$264M
| $1.32M | ﹤0.01% |
537,994
-135,590
| -20% | -$310K |
2026 Q1
1 quarter
|
|
2043
First Financial Bankshares
FFIN
$4.32B
| $1.32M | ﹤0.01% |
+38,078
| New | +$1.23M |
2026 Q2
0 quarters
|
|
2044
Xperi
XPER
$253M
| $1.32M | ﹤0.01% |
159,986
+99,725
| +165% | +$722K |
2025 Q4
2 quarters
|
|
2045
Ziff Davis
ZD
$1.98B
| $1.32M | ﹤0.01% |
25,126
-7,703
| -23% | -$349K |
2026 Q1
1 quarter
|
|
2046
State Street SPDR S&P Regional Banking ETF
KRE
$4.33B
| $1.31M | ﹤0.01% |
17,559
-85,716
| -83% | -$6M |
2024 Q2
8 quarters
|
|
2047
Vivid Seats
SEAT
$30.5M
| $1.31M | ﹤0.01% |
+201,297
| New | +$1.54M |
2026 Q2
0 quarters
|
|
2048
CALL
Thermo Fisher Scientific
TMO
$249B
| $1.3M | ﹤0.01% |
2,600
+1,500
| +136% | +$720K |
2026 Q1
1 quarter
|
|
2049
AirSculpt Technologies
AIRS
$86.5M
| $1.3M | ﹤0.01% |
289,586
+213,530
| +281% | +$866K |
2025 Q4
2 quarters
|
|
2050
InspireMD
NSPR
$21M
| $1.3M | ﹤0.01% |
1,860,405
| – | – |
2023 Q2
12 quarters
|
|
Similar funds
Marshall Wace's Q2 2026 Portfolio in Review
As of Q2 2026, Marshall Wace held 3,898 positions worth $127B, up 26% from $100B the previous quarter. Its ten largest holdings account for 38% of the portfolio.
Marshall Wace deployed $9.28B of net new capital in Q2 2026, opening 771 new positions and adding to 1,083 existing holdings. Its largest new stake was LPL Financial: 975,627 shares worth $275M.
By sector, the portfolio is most concentrated in Miscellaneous at 35% of assets, up from 30% a quarter earlier, followed by Technology and Consumer Discretionary.
On the sell side, the largest reduction was NVIDIA, an estimated $1.03B trimmed.
- Marshall Wace's largest Q2 2026 buy was LPL Financial: 975,627 shares worth $275M.
- Marshall Wace added most to iShares Core S&P 500 ETF in Q2 2026, an estimated $9.9B increase.
- Marshall Wace's biggest Q2 2026 reduction was NVIDIA, cutting an estimated $1.03B.
- Marshall Wace fully exited Merck in Q2 2026, selling an estimated $325M.
- Marshall Wace's ten largest holdings make up 38% of its $127B portfolio in Q2 2026.
- Marshall Wace opened 771 new positions and closed 795 in Q2 2026.
- Marshall Wace's portfolio value rose 26% quarter-over-quarter to $127B.
Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.